(Janus kinase 2) gene is Ͼ96% in PV cases and about 65% in ET and PMF cases. According to the 2008 WHO classification, the presence of this mutation is a major criterion for MPN diagnosis (1, 2 ) . Moreover, the burden of mutant alleles influences disease phenotype (3) (4) (5) and is associated with a greater risk of thrombosis in both ET (3 ) and PV (6 ) , as well as with disease progression in PMF (5, 7 ) . The molecular pathogenesis of the disorder in patients negative for the JAK2 V617F mutation is still unknown. Recently, activating somatic mutations in exon 10 of the myeloproliferative leukemia virus oncogene (MPL), which mainly involve a W515 substitution, were described in a minority of ET and PMF patients (8 -16 ) . Because the optimal approach for detecting low-abundance MPL variants has not yet been defined, innovative diagnostic assays with high analytical sensitivity and suitable for routine use are required. Such assays may become an important tool in the workup of MPN.
Given this need, our aim in this study was to substantially improve the strategy for scanning and genotyping MPL exon 10 W515 substitutions [W515L (1544 GϾT), W515K (1543-44 TGϾAA), and W515A (1543-44 TGϾGC)] in MPN patients. We adopted an innovative method, COLD-PCR (coamplification at lower denaturation temperature PCR), which preferentially enriches minority alleles. When coupled with downstream detection assays, COLD-PCR allows detection of molecular defects, even if they are present at very low levels (17) (18) (19) . We previously isolated DNA from granulocytes in blood samples obtained from 60 MPN patients and analyzed the DNA with highresolution melting (HRM), direct sequencing, and the TaqMan allelic-discrimination assay (20 ) . We have developed full COLD-PCR protocols and coupled them with direct sequencing for the identification of MPL mutations. Furthermore, in search of an alternative diagnostic strategy, we used a new microarray approach with slides coated with a special copolymer to set up assays that identify minority mutant alleles. We have successfully applied this system to detect minority fetal sequence variants in maternal plasma for noninvasive prenatal diagnosis of ␤-thalassemia and cystic fibrosis (21, 22 ) . We have taken advantage of this technology and developed reliable assays for MPL W515 substitutions that could be instrumental both for efficient and precise genotyping and for evaluating a patient's mutation burden. These assays may have important clinical and/or prognostic relevance for MPN patients.
Materials and Methods

PATIENTS
We evaluated 60 patients with ET or PMF for MPL mutations according to the 2008 diagnostic criteria of the WHO and the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (2, 23, 24 ) .
Detailed descriptions of the patients (20 ) , cell separation protocols, DNA isolation (25 ) , HRM, the TaqMan allelic-discrimination assay, and directsequencing procedures (20 ) are provided in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol58/ issue12.
PCR AND FULL COLD-PCR COUPLED WITH DIRECT SEQUENCING
To analyze granulocyte genomic DNA for MPL mutations, we used optimized primers to generate a 106-bp amplicon that bracketed the W515 region in MPL exon 10 (forward primer, 5Ј-AGCCTGGATCTCCTTG GTG-3Ј; reverse primer, 5Ј-GCGGTACCTGTAGT GTGCA-3Ј Sequencing was performed with the BigDye Terminator v1.1 Cycle Sequencing Kit and an ABI Prism 3730xl DNA Analyzer (Applied Biosystems). Sequence chromatograms were evaluated with the BioEdit biological sequence alignment editor (http://www.mbio. ncsu.edu/BioEdit/bioedit.html). Approximate estimates of a mutant nucleotide's abundance relative to the wild-type nucleotide were calculated from the peak heights of the chromatograms.
MICROARRAY
PCR conditions. For the detection of the MPL W515L, W515K, and W515A mutations, amino-modified amplicons (106 bp) were obtained by using optimized primers (forward, amino-modified-5Ј-AGCCTGGAT CTCCTTGGTG-3Ј; reverse, 5Ј-GCGGTACCTGTA GTGTGCA-3Ј). The PCR was performed in a 50-L volume under the same reaction conditions described for COLD-PCR. Cycling conditions were: 95°C for 4 min; 35 cycles of 95°C for 30 s, 61°C for 30 s, and 72°C for 30 s; and 72°C for 10 min. The PCR products were purified as previously described (21 ) .
Reporter and stabilizer design. Both the reporters specific for either the wild-type sequence or mutant sequences and the stabilizer oligonucleotides were designed with the help of programs available for free on the Web: DNA mfold server (http://mfold.rna. albany.edu/?qϭmfold/DNA-Folding-Form) and OligoAnalyzer 3.0 (Integrated DNA Technologies, http:// www.idtdna.com). We used a universal labeling format based on reporters containing a discriminator with a tail that hybridizes to either a universal Cy3-labeled or Cy5-labeled probe for wild type or mutant (26 ) . Further details about the reporters and stabilizer oligonucleotides are available in the online Data Supplement. All 3 MPL mutations on exon 10 (i.e., encoding W515L, W515K, and W515A) were analyzed with the same stabilizers and the same wild-type reporter. See the online Data Supplement for a detailed description of the preparation of the silicon chip coating and microarray (27 ) and for descriptions of the hybridization, image-scanning, and data-analysis steps (21, 28 ) .
Results
FULL COLD-PCR AND DIRECT SEQUENCING ASSAY
For the detection of the most frequent exon 10 W515 MPL substitutions, we identified the T c at which preferential denaturation of mutant sequences occurs, a crucial point in the establishment of a COLD-PCR protocol. We obtained the best enrichment at a T c value of 87.3°C and chose this temperature as the final T c of our assay. We applied 2 different cycling conditions to maximize enrichment for each mutation. Fig. 1 shows DNA samples from 3 MPN patients [which had previously been genotyped by HRM analysis and direct sequencing (20 ) ] that were amplified by conventional PCR and by full COLD-PCR and then sequenced. One patient (ID PV04_584), who carried the W515L mutant allele [GϾT conversion decreasing the T m (temperature at which 50% is denatured)] at 10% of MPL, and another patient (ID MPC07_289), who carried about 14% of the W515K mutant allele (a TGϾAA T mdecreasing conversion), had a 5-fold enrichment. The DNA sample extracted from a patient (ID MPC07_222), who carried about 50% W515A alleles (a TGϾGC T m -increasing conversion), was mixed with a wild-type sample to obtain a final mutant allele concentration of 5%. The COLD-PCR assay again showed a 5-fold enrichment. DNA samples from mutant controls that were heterozygous for the W515L mutation (50% mutant, 50% wild type) and homozygous for the W515K or W515A substitution (100% mutant) were then used to compare the analytical sensitivities of COLD-PCR and conventional PCR for detecting MPL exon 10 mutations. To this end, we mixed each DNA sample for the 3 mutant controls with different proportions of wild-type DNA samples to obtain defined percentages of mutant alleles (0%, 0.1%, 0.2%, 0.3%, 0.75%, 1.5%, 3%, 5%, 6.25%, 10%, and 12.5%). Under the optimized conditions, we determined that the different mutations had different limits of detection, with thresholds of 0.3% to 5%, depending on the particular mutation ( Fig. 2 ). We applied our optimized full COLD-PCR protocols for granulocyte DNA extracted from 60 MPN patients that had previously been characterized by HRM, direct sequencing, and the TaqMan allelic-discrimination assay (20 ) . Specifically, we analyzed DNA from 6 of 7 patients (DNA was unavailable for 1 patient) found to be variant by HRM, scored as wild type by direct sequencing, and analyzed by the TaqMan assay; from 10 patients found to have a mutation by HRM and direct sequencing; and from 44 patients characterized as wild type by HRM and direct sequencing. We included the patients in this last group to evaluate the possibility of false-positive results. Sixteen patients carried an MPL exon 10 substitution, DNA samples from patients heterozygous for the W515L mutation and homozygous for the W515A or W515K mutation were diluted to various percentages (0%-12.5% mutant DNA) with wild-type DNA samples. Shown are results for samples amplified by conventional PCR and by full COLD-PCR (T c ϭ 87.3°C). Direct-sequencing chromatograms (forward sequences) are shown along with the lowest percentage detected for each variant (black arrowheads). Base calling: M, A or C; S, G or C.
which confirmed the previous HRM data, and had varying proportions of minority mutant alleles ( Table  1) . The 44 patients in the third group were wild type, as expected (data not shown in Table 1 ). The 6 patients who were positive by HRM analysis and negative by direct sequencing were characterized. Five of the 6 samples carried the W515L mutation. The sixth sample, which was from patient MPC07_336 and previously found to be wild type by the TaqMan assay, was scored as having the W515K variant. In all of these cases, the mutant allele was not detected by conventional PCR and direct sequencing but became evident at different proportions after enrichment with full COLD-PCR (Fig. 3) .
MICROARRAY ANALYSIS
In parallel, we developed microarray assays to identify variants and to evaluate the proportion of mutations in exon 10 of the MPL gene. Optimal conditions for correctly identifying mutant alleles or the wild-type allele for the MPL W515L, W515K, and W515A mutations were determined for the microarray approach. Artificial homozygous and heterozygous controls for each substitution were used to set up conditions and test assay specificity. Fig. 4 illustrates an example that shows a hybridization experiment for the W515L mutation. As we did for the COLD-PCR assay, we assessed the analytical sensitivity of the system for detecting a minority allele by serially diluting a genomic DNA sample (range, 0%-12.5%) from controls that were heterozygous for the W515L mutation (50% mutant) and homozygous for the W515K or W515A variant, into a DNA sample from a wild-type control. Under the optimized conditions, the mutations were identified with different limits of detection, with thresholds of 0.1% to 5% depending on the specific mutation. Specifically, the assay's limit of detection was about 0.1% for the W515L mutation (Fig. 5A ) and 0.75% and 5% for the W515K and W515A mutations, respectively (data not shown). A plot of the linear regression for the serial dilution of the W515L mutant allele is presented in Fig. 1 in the online Data Supplement. We then studied genomic DNA samples prepared from granulocytes from a subset of 60 MPN patients from our cohort, which had previously been characterized by HRM, direct sequencing, and COLD-PCR (Table 1 and Fig. 5B ). Microarray analysis revealed that 16 patients carried a substitution in MPL exon 10, confirming the previous HRM and COLD-PCR data. There were varying proportions of minority mutant alleles, which we estimated after hybridization by comparing the wild-type and mutant fluorescence signals for each mutation. As expected, 44 of the patients were wild type. We then characterized the 6 patients that were mutant positive by HRM and COLD-PCR analysis and mutant negative by sequencing. Five of the 6 patients carried the W515L mutation. Patient MPC07_336 was scored as having the W515K mutation. Table 1 in the online Data Supplement compares the features of HRM, the TaqMan allelicdiscrimination assay, full COLD-PCR coupled with direct sequencing, and the microarray approach for analyzing MPL exon 10 mutations.
Discussion
The recent identification of W515 mutations in exon 10 of the MPL gene in patients with ET or PMF increased the proportion of patients found to carry a genetic lesion in the JAK/STAT (Janus kinase/signal transducer and activator of transcription) pathway (8, 9 ) . Although JAK2 and MPL mutations are not supposed to be primary causes of MPN, but rather secondary events associated with disease progression in a still unknown way, the acquisition of one of these gain-offunction mutations seems to be necessary for the development of the myeloproliferative phenotype. Moreover, the burden of mutant alleles influences the disease phenotype (3) (4) (5) and is associated with a greater risk of thrombosis in both ET (3 ) and PV (6 ), as well as with disease progression in PMF (5, 7 ) . Assays suitable for routine use are therefore required for detecting low-abundance MPL somatic mutations, and such assays will be an important tool in the workup of MPNs. Current diagnostic assays for MPL mutations include a TaqMan allelic-discrimination assay (only for the W515L and W515K substitutions) and direct sequencing, for which the limit of detection for minority mutant alleles is about 1.5% and 5%-20%, respectively. Moreover, the growing number of annotated mutations within MPL exon 10 (8, 9, 13, 29, 30 )-each of which requires a separate allele-specific reaction-renders such an approach impractical in a diagnostic laboratory, where assays that provide rapid screening are favored. Performing different allelespecific reactions for every patient sample is not an effective use of time or resources, and besides, this approach will miss unknown and novel mutations. Sequencing, considered the gold standard for mutational scanning and identification, is an alternative approach, but this methodology is also quite time-consuming, expensive, and analytically less sensitive than allelespecific approaches. The HRM assay is an analytically sensitive, rapid, and inexpensive screening technique for detecting all possible MPL exon 10 mutations and is particularly suitable for high-throughput applications (16, 20 ) . Depending on the type of mutation, the HRM assay is typically analytically more sensitive than sequencing, with thresholds of 1%-5% (20 ) . Nevertheless, although the most of the common MPL mutations are associated with distinctive HRM profiles, patients with abnormal HRM plots require a second test to identify the underlying mutation. Direct sequencing is clearly useful, but often it is not sufficiently analytically sensitive for confirmation (see Fig. 2 in the online Data Supplement for an example of a sample that HRM shows to be a variant but sequencing shows to be wild type). Furthermore, neither HRM nor the directsequencing approach is able to quantify specific mutant alleles.
To improve the detection of MPL mutations, we have developed alternative, innovative detection and genotyping methods that are based on 2 approaches: COLD-PCR coupled with direct sequencing, and microarrays. We first optimized conditions for the enrichment of tumor mutant alleles based on COLD-PCR coupled with direct sequencing. For the analysis of MPL exon 10 mutations with granulocyte genomic DNA, we developed protocols for full COLD-PCR that would cover a broad spectrum of mutation types. Indeed, full COLD-PCR has the capability to enrich for all types of mutations, even if the enrichment is modest and the amplification protocol is time-intensive. This capability is due to the hybridization step, compared with the fast COLD-PCR format, which is useful only for T m -decreasing mutations (17 ) . We optimized 2 different protocols, which have the same T c but different cycling conditions, to analyze W515 substitutions. One protocol enriches for W515L and W515K mutations, and the other enriches for the W515A variant. Interestingly, we obtained successful enrichment for the W515A mutation by shortening the duration of the T c step from 30 s (the optimal time for the W515L and W515K variants) to 3 s, although, in this case, the change in the number of cycles did not produce any improvement. We hypothesize that the various nucleotide substitutions may influence the melting behavior of the same DNA region differently, depending on cooperative contributions of adjacent nucleotides within the sequence microenvironment. For the 3 mutations we have studied, the optimized final protocols produced a mutant enrichment of about 5-fold, a finding consistent with data reported for other genes (17 ) . Depending on the type of mutation, our full COLD-PCR assays coupled with direct sequencing display limits of detection for nucleotide changes of 0.3% for W515K, 0.75% for W515L, and 5% for W515A, as measured by serial-dilution analysis. As these results indicate, enhancement by COLD-PCR was nonlinear and was more prominent when the concentrations of mutationcontaining sequences were lower, a finding that has been reported for other genes (31 ). The lower detection limit of W515A with respect to the other mutations could be ascribed to the increased GC percentage due to a TGϾGC substitution in the wild-type target region, which is already rich in G and C nucleotides. This feature may further affect the denaturation process and the T c time.
Hence, in our experiments, we verified that 3 s of the T c was sufficient to obtain a mutant enrichment of about 5-fold (the highest we obtained), whereas any further increase in the T c favored preferential denaturation of wildtype homoduplexes over mutant homo-and heteroduplexes. For greater enrichment of this mutation, the use of specific buffers of different ionic strength and composition might be of some utility. The COLD-PCR assays were then validated by mutation analysis with granulocyte DNA samples from 60 MPN patients that had previously been analyzed with HRM and direct sequencing. COLD-PCR confirmed the results for all patients who had been found to have either mutant or wild type by HRM, with no false-positive or -negative results. Moreover, we identified W515 nucleotide substitutions in DNA samples from 6 of 7 patients (DNA was unavailable for 1 patient) found to be variant by HRM, scored as wild type by direct sequencing, and analyzed by the TaqMan assay. The TaqMan assay identified 5 of the 6 samples as W515L. The sample from the sixth patient (ID MPC07_336), which the TaqMan assay had characterized as wild type, was identified as having the W515K variant by COLD-PCR coupled with direct sequencing. This finding suggests that the mutation burden was lower than the limit of detection of the TaqMan assay. Our findings indicate that COLD-PCR analysis of granulocyte DNA may be an optimal approach for studying large patient cohorts, for which it could be combined with direct sequencing for the molecular characterization of patients who been scored as having a variant by HRM.
One limitation of COLD-PCR is that the enrichment process obscures the true percentages of the mutant alleles and therefore does not permit an evaluation of the actual mutation burden, which could have important clinical and/or prognostic relevance for MPN patients. To address this issue, we developed microarray assays in parallel to improve mutation detection and permit semiquantitative genotyping of MPL mutations. Microarrays represent an analytically sensitive and accurate tool for parallel genotyping of multiple markers and, especially, for evaluating the mutantallele burden. This method is affordable, is easy to use, and, through the use unconventional microarray supports based on high-sensitivity silicon slides, can allow any variant to be identified. Samples in microarrays are characterized according to a "target/amplicon down" detection protocol, which we found to be much more efficient with respect to analytical sensitivity than a "capture down" format. To test assay specificity, we initially validated the system with wild-type and mutant control samples for all 3 MPL W515 substitutions. The optimized slide system produced high fluorescence signals and allowed correct identification of all control genotypes. The major advantage of the array is that several samples from different patients can be spotted on the same slide, thus allowing screening for disease-related mutations at up to 100 individuals per slide, making it particularly useful for screening large populations for important markers. Nevertheless, the drawback of this system is that the hybridization temperature must be carefully optimized for each mutation to obtain a specific genotype assignment. By using microarrays, we obtained limits of detection for the nucleotide changes of 0.1% for W515L, 0.75% for W515K, and 5% for W515A. Notably, this unusual kind of microarray, which is coated with an innovative special copolymer, displayed an analytical sensitivity similar to that obtained with COLD-PCR, without a need for any enrichment protocol. This feature allowed evaluations of the proportions of mutant and wild-type alleles. Subsequent microarray validation with 60 granulocyte DNA samples from MPN patients that had previously been analyzed with HRM, COLD-PCR coupled with sequencing, and the TaqMan assay showed 100% concordance of results for the different approaches. Moreover, microarrays allowed characterization of the proportion of each mutant allele in every patient. In particular, 1 patient (ID MPC07_336) was scored as having the W515K mutant and an allele burden of approximately 0.8%, thus confirming the positive result obtained with COLD-PCR and explaining why this low allele percentage was not detected in the TaqMan assay. The results obtained by the microarray approach provide further confirmation that these new slides are easy to use and have such a high sensitivity that the system has the potential for successful application to directly detect any sequence variant.
In summary, the diagnostic strategy often cannot rely on a unique approach in the molecular analysis of pathologies characterized by the presence of minority mutant alleles. We developed 2 innovative and highly analytically sensitive methods for detecting and characterizing mutations in MPL exon 10. Theoretically, these methods can be coupled with established protocols for a combined and flexible approach. HRM may be used for scanning and identifying variants in samples, and such variants can be characterized further via enrichment of mutant alleles by COLD-PCR, coupled with direct sequencing. Alternatively, microarrays may allow both genotyping and evaluation of the mutant burden, without any enrichment strategy. This approach should extendable to other genes recently found to be involved in myeloid neoplasms or to any other genetic clinical situations, and it has the potential to be transferable to clinical diagnostic laboratories. It may allow diagnoses of the disease state at the earliest stage, provide relevant prognostic information, and represent a basis for stratifying the risks and implementing risk-adapted treatment strategies. 
